Search Filters
Advanced Search
SMC ID Date Medicine Submission Type Indication
SMC2733 07/07/2025 selpercatinib (Retsevmo) Full

As monotherapy for the treatment of adults and adolescents 12 years and older with advanced RET fusion-positive thyroid cancer who are radioactive iodine-refractory (if radioactive iodine is appropriate).
SMC2754 10/03/2025 cabozantinib (Cabozantinib Ipsen) Abbreviated

As monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.
SMC2370 13/09/2021 selpercatinib (Retsevmo) Full

Adults and adolescents 12 years and older with advanced RET-mutant medullary thyroid cancer (MTC) who require systemic therapy following prior treatment with cabozantinib and/or vandetanib.
Adults with advanced RET fusion-positive thyroid cancer (TC) who require systemic therapy following prior treatment with lenvatinib and/or sorafenib.
SMC2246 11/11/2019 ramucirumab (Cyramza) Non submission
1316/18 07/05/2018 regorafenib (Stivarga) Full As a monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously tretated with sorafenib
482/08 11/01/2016 sorafenib (Nexavar) Resubmission For the treatment of hepatocellular carcinoma.
1055/15 13/07/2015 sorafenib (Nexavar) Full Treatment of patients with progressive, locally advanced or metastatic, differentiated thyroid carcinoma, refractory to radioactive iodine.
321/06 13/11/2006 sorafenib 200mg tablets (Nexavar) Full Renal cell carcinoma

No medicines have been found.